PointState Capital’s Bristol-Myers Squibb BMY Stock Holding History

PointState Capital’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-47,235	Closed	-$3.64M	–	54
2022 Q2	$3.64M	Buy	+47,235	New	+$3.6M	0.09%	46
2022 Q1	–	Sell	-77,500	Closed	-$4.83M	–	80
2021 Q4	$4.83M	Buy	+77,500	New	+$4.55M	0.08%	91
2021 Q1	–	Sell	-76,828	Closed	-$4.77M	–	128
2020 Q4	$4.77M	Buy	+76,828	New	+$4.72M	0.09%	95
2019 Q2	–	Sell	-2,244,489	Closed	-$107M	–	117
2019 Q1	$107M	Buy	+2,244,489	New	+$112M	2.11%	16
2017 Q4	–	Sell	-20,000	Closed	-$1.27M	–	159
2017 Q3	$1.27M	Sell	20,000 -2,139,250	-99%	-$125M	0.01%	147
2017 Q2	$120M	Sell	2,159,250 -480,050	-18%	-$26.1M	1.31%	26
2017 Q1	$144M	Buy	2,639,300 +2,382,000	+926%	+$131M	1.5%	21
2016 Q4	$15M	Buy	+257,300	New	+$14.1M	0.22%	80

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PointState Capital's BMY Position: Q3 2022 in Review

PointState Capital sold out of Bristol-Myers Squibb (BMY) in Q3 2022, closing a stake of 47,235 shares — an estimated $3.64M sold.

PointState Capital first reported a position in BMY in Q4 2016 and held it in 8 quarters. The position peaked at $144M in Q1 2017. 2,470 funds tracked by Wall St. Rank hold BMY as of Q3 2022.

PointState Capital reported no remaining Bristol-Myers Squibb position as of Q3 2022 after selling out during the quarter.
PointState Capital sold 47,235 Bristol-Myers Squibb shares in Q3 2022, an estimated $3.64M.
PointState Capital first reported a position in Bristol-Myers Squibb in Q4 2016 and held it in 8 quarters.
PointState Capital's Bristol-Myers Squibb position peaked at $144M in Q1 2017.
2,470 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2022.

Based on PointState Capital's 13F filing for Q3 2022, filed 10 Nov 2022.